For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
Basic information |
Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
Jessica Wu |
Chen-En Tsai |
Jessica Wu |
02-26571788 |
8F, No.41, Lane 221, Kang Chien Rd.,Nei Hu Dist., Taipei 11494, Taiwan |
2016/12/27 |
Industrycategory |
Key businesses |
Biotechnology and Medical Care |
TWi Biotechnology is dedicated to developing new drugs for innate immunity-related diseases,including diabetes mellitus,gout,ophthalmic and dermal conditions,and others.The strategy of TWi Biotechnology is to focus on the development of treatments for unmet medical needs,such as severe rare diseases without therapies, or treatments that represent a significant breakthrough for the disease. In order to achieve these goals in a highly efficient manner, and to provide safe and effective new drugs to patients with urgent needs, TWi Biotechnology has adopted a drug repositioning strategy. While based in Taiwan, TWi Biotechnology is targeting United States as its primary market. |
Financial data |
Cash flows statement
| Item
|
|
|
Amount(NTD, in thousands) |
Cash flows from operating activities |
|
|
Cash flows from investing activities |
|
|
Cash flows from financing activities |
|
|
Consolidated/Individual balance sheet
|
Current assets |
|
|
Non-current assets |
|
|
Total assets |
|
|
Current liabilities |
|
|
Non-current liabilities |
|
|
Total liabilities |
|
|
Share capital |
|
|
Capital surplus |
|
|
Retained earnings |
|
|
Other equity interest |
|
|
Treasury shares |
|
|
Total equity attributable to owners of parent |
|
|
Non-controlling interests |
|
|
Total equity |
|
|
Book Value per share(NT$) |
|
|
Consolidated/Individual profit and loss statement |
Operating revenue |
|
|
Operating costs |
|
|
Gross profit from operations |
|
|
Operating expenses |
|
|
Net other income (expenses) |
|
|
Net operating income |
|
|
Non-operating income and expenses |
|
|
Profit before tax |
|
|
Tax expense |
|
|
Profit from continuing operations |
|
|
Profit from discontinued operations |
|
|
Profit |
|
|
Other comprehensive income |
|
|
Comprehensive income |
|
|
Basic earnings per share |
|
|
Auditor's report on latest financial statements: auditor's report:
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|